search
Back to results

Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Lacidipine
Sponsored by
Boehringer Ingelheim
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

20 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Fulfillment of entry criteria for the preceding yearly study
  • Male or female patients aged between 20 and 85 years
  • Known history of mild to moderate essential hypertension requiring drug treatment, WHO grade I to II
  • Controlled blood pressure (RR diastolic ≤ 90 mm Hg or 91 - 95 mm Hg and concurrent reduction in blood pressure of at least 10 mm compared to baseline level) during treatment with lacidipine at a dose of 2 - 6 mg once a day
  • Final visit of the previous yearly study (Visit 4) completed as scheduled
  • Informed consent to participate in the follow-up study

Exclusion Criteria:

  • Violation of entry/exclusion criteria on enrolment in the preceding yearly study
  • Occurrence of the following exclusion criteria in the intervening period:

    • Pregnancy, lactation, possibility of conception without the use of a scientifically recognised method of contraception
    • Secondary form of hypertension
    • Consumptive illness
    • Clinically manifest concomitant cardiovascular illness, e.g.: aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy or any other condition hindering left ventricular outflow, aortic isthmus stenosis, severe (NYHA Class III or higher) or decompensated heart failure, clinically relevant hypo- or hyperkinetic cardiac arrhythmia
    • Myocardial infarction or cerebrovascular accident within the 6 months prior to the start of the follow-up study
    • Hypersensitivity to dihydropyridines
    • Concomitant long-term treatment (> 3 weeks) with antihypertensive substances not envisaged in the protocol (exception: short-acting nitrates), sedatives, tricyclic antidepressants
    • Suspected alcohol, narcotic or drug abuse

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Lacidipine

    Arm Description

    Outcomes

    Primary Outcome Measures

    Number of patients with rare adverse drug reactions
    Change in alkaline phosphatase (AP)
    Change in serum glutamic - pyruvic transaminase (SGPT)

    Secondary Outcome Measures

    Change in serum glutamic - oxaloacetic transaminase (SGOT)
    Number of patients with abnormal changes in laboratory parameters
    Changes in systolic and diastolic blood pressure
    Changes in gamma glutamyl transferase (gamma-GT)

    Full Information

    First Posted
    June 24, 2014
    Last Updated
    July 11, 2014
    Sponsor
    Boehringer Ingelheim
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02177331
    Brief Title
    Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension
    Official Title
    Lacidipine in Medical Practice: Incidence of Rare Adverse Drug Reactions During Long-term Treatment. 3rd Follow-up Study - Long-term Use in the 4th and 5th Year Treatment Years
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2014
    Overall Recruitment Status
    Completed
    Study Start Date
    June 1995 (undefined)
    Primary Completion Date
    January 1998 (Actual)
    Study Completion Date
    undefined (undefined)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Boehringer Ingelheim

    4. Oversight

    5. Study Description

    Brief Summary
    In order to confirm the proposed metabolic effect of lacidipine these follow-up study was to provide long-term data on its impact on liver function, glucose homoeostasis and lipid metabolism. Additionally, its adverse drug reactions and antihypertensive effects were to be studied.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    53 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Lacidipine
    Arm Type
    Experimental
    Intervention Type
    Drug
    Intervention Name(s)
    Lacidipine
    Primary Outcome Measure Information:
    Title
    Number of patients with rare adverse drug reactions
    Time Frame
    up to 24 months
    Title
    Change in alkaline phosphatase (AP)
    Time Frame
    up to 24 months
    Title
    Change in serum glutamic - pyruvic transaminase (SGPT)
    Time Frame
    up to 24 months
    Secondary Outcome Measure Information:
    Title
    Change in serum glutamic - oxaloacetic transaminase (SGOT)
    Time Frame
    up to 24 months
    Title
    Number of patients with abnormal changes in laboratory parameters
    Time Frame
    up to 24 months
    Title
    Changes in systolic and diastolic blood pressure
    Time Frame
    up to 24 months
    Title
    Changes in gamma glutamyl transferase (gamma-GT)
    Time Frame
    up to 24 month

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    20 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Fulfillment of entry criteria for the preceding yearly study Male or female patients aged between 20 and 85 years Known history of mild to moderate essential hypertension requiring drug treatment, WHO grade I to II Controlled blood pressure (RR diastolic ≤ 90 mm Hg or 91 - 95 mm Hg and concurrent reduction in blood pressure of at least 10 mm compared to baseline level) during treatment with lacidipine at a dose of 2 - 6 mg once a day Final visit of the previous yearly study (Visit 4) completed as scheduled Informed consent to participate in the follow-up study Exclusion Criteria: Violation of entry/exclusion criteria on enrolment in the preceding yearly study Occurrence of the following exclusion criteria in the intervening period: Pregnancy, lactation, possibility of conception without the use of a scientifically recognised method of contraception Secondary form of hypertension Consumptive illness Clinically manifest concomitant cardiovascular illness, e.g.: aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy or any other condition hindering left ventricular outflow, aortic isthmus stenosis, severe (NYHA Class III or higher) or decompensated heart failure, clinically relevant hypo- or hyperkinetic cardiac arrhythmia Myocardial infarction or cerebrovascular accident within the 6 months prior to the start of the follow-up study Hypersensitivity to dihydropyridines Concomitant long-term treatment (> 3 weeks) with antihypertensive substances not envisaged in the protocol (exception: short-acting nitrates), sedatives, tricyclic antidepressants Suspected alcohol, narcotic or drug abuse

    12. IPD Sharing Statement

    Links:
    URL
    http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/231/231.215_U99-1368.pdf
    Description
    Related Info

    Learn more about this trial

    Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension

    We'll reach out to this number within 24 hrs